AbbVie Reports Third-Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
AbbVie (ABBV) shares dip as revenue drops 6% from last year
October 27, 2023 9:58 AM EDTAbbVie (NYSE: ABBV) shares dipped at the open Friday despite reporting its latest quarterly earnings that beat consensus expectations.
The pharmaceutical firm reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87, while revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.
The company's revenue dipped 6% from a year ago. Revenues from its immunology portfolio fell 11.3%, while its oncology segment... More
AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
October 27, 2023 7:40 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.
GUIDANCE:
AbbVie sees Q4 2023 EPS of $11.19-$11.23, versus the consensus of $11.06.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More